stockrowCVRx, Inc.
CVRX Healthcare Medical Devices
CVRx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $56.7 million, up 10.4% from fiscal 2024.
- Revenue
- −5.84%
- EPS
- −6.12%
- Free cash flow
- −9.91%
- Total debt
- +18.6%
Quarter to September 2026, against a year earlier
Follow CVRX
Alert me
CVRx, Inc. (CVRX) EV/Sales
As of 5 November 2026, CVRx, Inc. (CVRX) trades at a EV/Sales of 0.7×. Over the past ten years it has ranged from −4.9× (March 2022) to 21.5× (November 2021); the current reading is higher than 15% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.9× | (36.91%) |
| FY2024 | 4.5× | (68.95%) |
| FY2023 | 14.6× | 13.93% |
| FY2022 | 12.8× | 3,967.97% |
| FY2021 | 0.3× | — |
| FY2020 | −2.1× | — |
| FY2019 | −2.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 0.8× | (61.34%) |
| Jun 2026 | 2.2× | (46.00%) |
| Mar 2026 | 4.0× | 41.09% |
| Dec 2025 | 2.9× | (10.32%) |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| XTNT Xtant Medical Holdings, Inc. compare | 0.5× |
| SNWV Sanuwave Health Inc. compare | 0.7× |
| CVRX CVRx, Inc. | 0.7× |
| RPID Rapid Micro Biosystems, Inc. compare | 0.8× |
| TELA TELA Bio, Inc. compare | 1.0× |
| MYO Myomo, Inc. compare | 1.1× |
| NSPR InspireMD, Inc. compare | 2.5× |
| MDAI Spectral AI, Inc. compare | 2.7× |
| ELUT Elutia Inc. compare | 3.4× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)